BeiGene announces Ontario, Quebec publicly list Brukinsa to treat CLL

On Wednesday, BeiGene announced that the Governments of Ontario and Quebec have publicly listed Brukinsa, a second generation inhibitor of Bruton’s tyrosine kinase, or BTK, for the treatment of adults living with chronic lymphocytic leukemia, or CLL, the most common form of leukemia in adults. The Regie de l’assurance maladie du Quebec listing came into effect December 13, 2023, and the Ontario Drug Benefit Program added Brukinsa on January 12.